Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 210278, held by Glenmark Pharms Ltd. Topiramate.
As of Nov 15, 2026, ANDA 210278 (Topiramate), held by Glenmark Pharms Ltd, was first approved by FDA on Feb 1, 2021, with 4 approved supplements and 0 published complete response letters.
Topiramate extended-release capsules are indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2021 | Original application | Approved |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate150MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
| Nov 26, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 7, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 21, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 21, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 1, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters